BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1466 related articles for article (PubMed ID: 17462723)

  • 1. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
    Kerkmeijer LG; Wielsma S; Massuger LF; Sweep FC; Thomas CM
    Gynecol Oncol; 2007 Jul; 106(1):142-6. PubMed ID: 17462723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent trophoblast disease following partial molar pregnancy.
    Wielsma S; Kerkmeijer L; Bekkers R; Pyman J; Tan J; Quinn M
    Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):119-23. PubMed ID: 16638033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines following hydatidiform mole: a reappraisal.
    Kerkmeijer L; Wielsma S; Bekkers R; Pyman J; Tan J; Quinn M
    Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):112-8. PubMed ID: 16638032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy.
    Wolfberg AJ; Feltmate C; Goldstein DP; Berkowitz RS; Lieberman E
    Obstet Gynecol; 2004 Sep; 104(3):551-4. PubMed ID: 15339768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of gestational trophoblastic disease for longer than 1 year following evacuation of hydatidiform mole.
    Elmer DB; Granai CO; Ball HG; Curry SL
    Obstet Gynecol; 1993 May; 81(5 ( Pt 2)):888-90. PubMed ID: 7682320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease.
    Thomas CM; Kerkmeijer LG; Ariaens HJ; van der Steen RC; Massuger LF; Sweep FC
    Gynecol Oncol; 2010 Apr; 117(1):47-52. PubMed ID: 20116088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of macrophage colony-stimulating factor in trophoblastic disease.
    Kohorn EI; Kacinski BM; Stanley ER
    Gynecol Oncol; 2001 Mar; 80(3):383-6. PubMed ID: 11263936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy.
    Wolfberg AJ; Growdon WB; Feltmate CM; Goldstein DP; Genest DR; Chinchilla ME; Berkowitz RS; Lieberman ES
    Obstet Gynecol; 2006 Aug; 108(2):393-6. PubMed ID: 16880311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of CA-125 in trophoblastic disease.
    Kohorn EI
    Gynecol Oncol; 2000 Jul; 78(1):39-42. PubMed ID: 10873407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
    Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
    Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma human chorionic gonadotropin disappearance in hydatidiform mole: a central registry report from the Netherlands.
    Franke HR; Risse EK; Kenemans P; Houx PC; Stolk JG; Vooijs GP
    Obstet Gynecol; 1983 Oct; 62(4):467-73. PubMed ID: 6888825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of women with recurrent molar pregnancies.
    Lorigan PC; Sharma S; Bright N; Coleman RE; Hancock BW
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):288-92. PubMed ID: 10985882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of prophylactic chemotherapy outcome and clinical characteristics in patients of high-risk hydatidiform mole].
    Geng S; Feng FZ; Xiang Y; Wan XR; Zhou Y
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):24-7. PubMed ID: 21429430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of pregnancies occurring before completion of human chorionic gonadotropin follow-up in patients with persistent gestational trophoblastic tumor.
    Tuncer ZS; Bernstein MR; Goldstein DP; Berkowitz RS
    Gynecol Oncol; 1999 Jun; 73(3):345-7. PubMed ID: 10366457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
    Shaarawy M; Darwish NA; Abdel-Aziz O
    J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum SP1, hPL and beta-hCG levels in trophoblastic diseases.
    Zhang WY; Yen GL
    Chin Med J (Engl); 1991 Dec; 104(12):995-8. PubMed ID: 1723674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent low-level "real" human chorionic gonadotropin: a clinical challenge and a therapeutic dilemma.
    Kohorn EI
    Gynecol Oncol; 2002 May; 85(2):315-20. PubMed ID: 11972394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study.
    Kim BW; Cho H; Kim H; Nam EJ; Kim SW; Kim S; Kim YT; Kim JH
    Eur J Obstet Gynecol Reprod Biol; 2012 Jan; 160(1):100-5. PubMed ID: 22055909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy.
    Wolfberg AJ; Berkowitz RS; Goldstein DP; Feltmate C; Lieberman E
    Obstet Gynecol; 2005 Sep; 106(3):548-52. PubMed ID: 16135585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum progesterone monitoring in post-molar surveillance.
    Vasilev SA; Schlaerth JB; Ahn C; Sauer MV
    Gynecol Oncol; 1994 Sep; 54(3):288-91. PubMed ID: 7522199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.